PTK2 and neoplasm: Thus, to evaluate the impact of FAK inhibition on mTORC1i efficacy in a more relevant biological setting that includes the tumor microenvironment, we transitioned to assessing the impact of adding FAK inhibitors to mTORC1 inhibition using in vivo models.